Imatinib mesylate does not impair the immunogenicity of human myeloid blood dendritic cells.
Wehner
R
R
Wendisch
M
M
Schäkel
K
K
Bornhäuser
M
M
Platzbecker
U
U
Mohr
B
B
Temme
A
A
Bachmann
M
M
Rieber
E P
EP
Schmitz
M
M
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001549:Benzamides; D003713:Dendritic Cells / Q000187:drug effects* / Q000276:immunology; D005434:Flow Cytometry; D006801:Humans; D000068877:Imatinib Mesylate; D016130:Immunophenotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D010879:Piperazines / Q000494:pharmacology* / Q000627:therapeutic use; D011743:Pyrimidines / Q000494:pharmacology* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate